Whilst minimal-rely MBL almost never progresses to CLL, higher-count MBL progresses to CLL requiring therapy in a price of 1% to 2% a year. Higher-depend MBL is distinguished from Rai 0 CLL depending on if the B-cell count is earlier mentioned or beneath five × 109/L. Though people with each substantial-depend MBL and CLL Rai phase 0 are at enhanc